Targeting heparin and heparan sulfate protein interactions

被引:128
作者
Weiss, Ryan J. [1 ]
Esko, Jeffrey D. [1 ]
Tor, Yitzhak [2 ]
机构
[1] Univ Calif San Diego, Glycobiol Res & Training Ctr, Dept Cellular & Mol Med, La Jolla, CA 92093 USA
[2] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA
基金
美国国家卫生研究院;
关键词
HERPES-SIMPLEX-VIRUS; LOW-MOLECULAR-WEIGHT; FIBROBLAST-GROWTH-FACTOR; HUMAN-IMMUNODEFICIENCY-VIRUS; TO-CELL SPREAD; HUMAN-PAPILLOMAVIRUS INFECTION; HEREDITARY MULTIPLE EXOSTOSES; PLACEBO-CONTROLLED TRIAL; CHRONIC HEPATITIS-C; ALZHEIMERS-DISEASE;
D O I
10.1039/c7ob01058c
中图分类号
O62 [有机化学];
学科分类号
070303 ; 081704 ;
摘要
Heparin and heparan sulfate glycosaminoglycans are long, linear polysaccharides that are made up of alternating dissacharide sequences of sulfated uronic acid and amino sugars. Unlike heparin, which is only found in mast cells, heparan sulfate is ubiquitously expressed on the cell surface and in the extracellular matrix of all animal cells. These negatively-charged glycans play essential roles in important cellular functions such as cell growth, adhesion, angiogenesis, and blood coagulation. These biomolecules are also involved in pathophysiological conditions such as pathogen infection and human disease. This review discusses past and current methods for targeting these complex biomolecules as a novel therapeutic strategy to treating disorders such as cancer, neurodegenerative diseases, and infection.
引用
收藏
页码:5656 / 5668
页数:13
相关论文
共 234 条
[1]   Heparin induced thrombocytopenia: diagnosis and management update [J].
Ahmed, I. ;
Majeed, A. ;
Powell, R. .
POSTGRADUATE MEDICAL JOURNAL, 2007, 83 (983) :575-582
[2]   Substrate specificity and domain functions of extracellular heparan sulfate 6-O-endosulfatases, QSulf1 and QSulf2 [J].
Ai, XB ;
Do, AT ;
Kusche-Gullberg, M ;
Lindahl, U ;
Lu, K ;
Emerson, CP .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (08) :4969-4976
[3]  
Al-Jamal Khuloud T, 2012, Results Pharma Sci, V2, P9, DOI 10.1016/j.rinphs.2011.12.002
[4]   Structural features of glycol-split low-molecular-weight heparins and their heparin lyase generated fragments [J].
Alekseeva, Anna ;
Casu, Benito ;
Cassinelli, Giuseppe ;
Guerrini, Marco ;
Torri, Giangiacomo ;
Naggi, Annamaria .
ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2014, 406 (01) :249-265
[5]  
AlvarezDominguez C, 1997, INFECT IMMUN, V65, P78
[6]   Anti-HSV activity of lactoferrin and lactoferricin is dependent on the presence of heparan sulphate at the cell surface [J].
Andersen, JH ;
Jenssen, H ;
Sandvik, K ;
Gutteberg, TJ .
JOURNAL OF MEDICAL VIROLOGY, 2004, 74 (02) :262-271
[7]   Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin [J].
Ansell, Jack E. ;
Laulicht, Bryan E. ;
Bakhru, Sasha H. ;
Hoffman, Maureane ;
Steiner, Solomon S. ;
Costin, James C. .
THROMBOSIS RESEARCH, 2016, 146 :113-118
[8]   Modular Synthesis of Heparan Sulfate Oligosaccharides for Structure-Activity Relationship Studies [J].
Arungundram, Sailaja ;
Al-Mafraji, Kanar ;
Asong, Jinkeng ;
Leach, Franklin E., III ;
Amster, I. Jonathan ;
Venot, Andre ;
Turnbull, Jeremy E. ;
Boons, Geert-Jan .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2009, 131 (47) :17394-17405
[9]   Self-assembling lipid modified glycol-split heparin nanoparticles suppress lipopolysaccharide-induced inflammation through TLR4-NF-κB signaling [J].
Babazada, Hasan ;
Yamashita, Fumiyoshi ;
Yanamoto, Shinya ;
Hashida, Mitsuru .
JOURNAL OF CONTROLLED RELEASE, 2014, 194 :332-340
[10]   Chemokines in pathology and medicine [J].
Baggiolini, M .
JOURNAL OF INTERNAL MEDICINE, 2001, 250 (02) :91-104